GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison of Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Rapid Therapeutic Science Laboratories Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201
Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.
Executives
Henry Anthony Punzi director 1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin director 639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier 10 percent owner 7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr. director, 10 percent owner, officer: President and CEO 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson director, officer: Chief Operating Officer 2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc. 10 percent owner 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler director, officer: CFO 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond director, officer: CFO 28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson director, officer: CEO and President 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130